Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

PDF  |  How to cite

Oncotarget. 2020; 11:942-942. https://doi.org/10.18632/oncotarget.27512

Metrics: PDF 664 views  |   ?  

David M. Goldenberg1, Thomas M. Cardillo1, Serengulam V. Govindan1, Edmund A. Rossi1, Robert M. Sharkey1

1 Immunomedics, Inc., Morris Plains, NJ, USA
* Presented in part as a lecture by DMG, “Challenging the Dogmas: Clinical Efficacy of SN-38-conjugated Antibodies in Solid Tumors,” at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapy, Barcelona, Spain, November 20, 2014.

Published: March 10, 2020

This article has been corrected: Due to an entry error found in one of the triplicate data for the 48-h time-point of stability in human serum in vitro, the half-life for drug release has been corrected to 18.82 h from the stated 23.98 h in Figure 1C. The corrected Figure 1C is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2015; 6:22496–22512. DOI: https://doi.org/10.18632/oncotarget.4318.

Figure 1: Structures of irinotecan, SN-38, and CL2A-SN-38. (C) In vitro serum stability of IMMU-132 in monkey or human serum.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27512